Press Releases

 
Press Releases
  Date Title and Summary View
Apr 11, 2016
SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, April 11, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) and Dong-A ST Co., Ltd. (170900: Korea SE), today announced that the companies have entered into two separate licensing agreements. Tobira has acquired exclusive rights to develop and market evogliptin in combination with ceni...
Apr 5, 2016
SOUTH SAN FRANCISCO, Calif., April 5, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the 15th Annual Needham Healthcare Conference. Location: New York Presentation date: Tuesday, April 12, 2016 Presentation time: 2:20 p.m. ET A l...
Mar 30, 2016
SOUTH SAN FRANCISCO, Calif., March 30, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced an upcoming data presentation at the 51st Annual Meeting of the European Associatio...
Mar 28, 2016
SOUTH SAN FRANCISCO, Calif., March 28, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, will host a live webcast in conjunction with its Analyst and Investor Day on Monday, April...
Mar 9, 2016
SOUTH SAN FRANCISCO, Calif., March 9, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today announced that the description of the fully-enrolled CENTAUR Phase 2b clinical trial ...
Mar 3, 2016
SOUTH SAN FRANCISCO, Calif., March 3, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the three and 12 months ended ...
Mar 1, 2016
SOUTH SAN FRANCISCO, Calif., March 1, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences in March. The Cowen and Company 36th Annual Healthcare Conference Presentation date: Tuesday, March 8, 2016 Presentatio...
Feb 22, 2016
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a biopharmaceutical company developing novel treatments for nonalcoholic steatohepatitis (NASH), and other serious immuno-inflammatory and fibrotic diseases, will report financial results for the quarter ended December 31, 2015 after market close...
Feb 9, 2016
SOUTH SAN FRANCISCO, Calif., Feb. 9, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, announced that it has completed recruitment for the Phase 2a ORION study. ORION is a...
Feb 1, 2016
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences in February. 18th Annual BIO CEO & Investor Conference Presentation date: Tuesday, February 9, 2016 Presentation time: 3...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase